YOLFTbeta
Genfit S.A.

Genfit S.A.

GNFT · PA · Healthcare / Biotechnology

10.70EUR-0.14 (-1.29%)

Price History

Full chart

Market Stats

Previous Close10.84
Open10.76
Day Range10.44 – 11.00
52-Week Range3.37 – 15.48
Volume161.22K
Market Cap455.88M
P/E (TTM)0.00
Forward P/E7.55
EPS-1.72
Dividend Yield0.00%
Beta1.13
50-Day Avg12.78
200-Day Avg9.62

About

Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, which is in Phase 1b clinical trial for the treatment of cholangiocarcinoma; and G1090N/NTZ, which is in Phase 1 clinical trial for the treatment of acute-on-chronic liver failure continuum. In addition, the company is involved in the development of drugs in preclinical stage, including SRT-015, CLM-022, and EViv for the treatment of acute-on-chronic liver failure continuum; VS-02-HE for the treatment of hepatic encephalopathy; and VS-01-HAC (UCD/OA) for the treatment of hyperammonemic crises, urea cycle disorder, and organic acidemias. It has strategic partnerships with Ipsen for the development and commercialization of elafibranor; and Labcorp for the development and commercialization of NASHnext, a blood-based molecular diagnostic test, as well as TS-01, a diagnostic tool for blood ammonia levels. The company was incorporated in 1999 and is headquartered in Loos, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. M. Pascal Prigent
  • Employees161
  • HeadquartersParc Eurasanté, Loos, France, 59120, France
  • Websitehttps://www.genfit.com

Leadership

  • Mr. Jean-Francois MouneyCo-Founder & Chairman of the Board · b. 1955
  • Mr. M. Pascal PrigentChief Executive Officer · b. 1968
  • Mr. John BrozekExecutive VP of Data & Information Technology and Director · b. 1977
  • Prof. Bart StaelsCo-Founder & Chairman of the Scientific Advisory Board · b. 1963
  • Mr. Thomas BaetzChief Financial Officer · b. 1974
  • Mr. Pascal CaiseyDeputy CEO & COO · b. 1968
  • Ms. Sakina Sayah-JeanneChief Scientific Officer · b. 1972
  • Mr. Jean-Christophe MarcouxChief Corporate Affairs Officer, Head of Investor Relations & Head of ESG · b. 1977
  • Mr. Laurent LannooCorporate Secretary & Director of Legal Affairs · b. 1970
  • Ms. Stefanie Magner J.D.Chief Compliance Officer & Executive VP of International Legal Affairs · b. 1981

Financials

Income Statement

Currency: EUR2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue10.82M12.41M12.77M10.05M9.48M8.76M5.81M3.76M2.36M1.67M1.90M1.61M527.00K284.00K118.00K69.00K30.84M765.00K80.07M20.20M28.57M67.00M65.43M
Growth (%)-+14.71%+2.94%-21.31%-5.72%-7.56%-33.66%-35.35%-37.17%-29.17%+13.57%-15.00%-67.36%-46.11%-58.45%-41.53%+44594.20%-97.52%+10366.54%-74.78%+41.45%+134.56%-2.34%
Cost of Revenue7.08M1.91M1.32M1.69M2.01M1.74M1.61M1.37M1.41M1.20M1.29M1.40M1.93M1.99M2.23M1.85M177.00K202.00K161.00K248.00K341.00K300.00K50.88M
Gross Profit-10.50M11.46M8.37M7.47M7.02M4.21M2.39M949.30K477.20K606.40K210.10K-1.40M-1.70M-2.11M-1.78M30.66M563.00K79.91M19.95M28.22M66.70M14.55M
Gross Margin-84.62%89.68%83.23%78.84%80.10%72.37%63.57%40.21%28.54%31.93%13.01%-266.41%-598.94%-1788.98%-2586.96%99.43%73.59%99.80%98.77%98.81%99.55%22.24%
Operating Expense-7.81M9.78M8.92M13.46M12.19M10.68M10.05M8.70M8.19M11.12M17.47M16.27M32.46M54.58M67.70M88.49M83.46M48.09M47.50M54.80M63.42M73.47M
Operating Income2.93M2.69M1.68M-553.30K-5.99M-5.17M-6.47M-7.66M-7.75M-7.72M-10.51M-17.26M-17.68M-34.16M-56.70M-69.48M-57.83M-82.90M31.82M-27.55M-26.58M3.28M-58.92M
Operating Margin27.08%21.67%13.12%-5.50%-63.21%-59.06%-111.40%-203.82%-328.32%-461.39%-553.56%-1069.04%-3354.08%-12027.46%-48046.61%-100701.45%-187.53%-10836.21%39.74%-136.41%-93.05%4.90%-90.05%
EBITDA-3.66M2.60M930.30K-4.07M-3.41M-5.09M-6.53M-6.64M-6.77M-9.95M-16.98M-17.35M-33.53M-55.76M-68.08M-49.03M-73.03M71.89M-23.60M-22.24M8.35M-8.04M
EBITDA Margin-29.50%20.38%9.25%-42.93%-38.90%-87.60%-173.87%-281.18%-405.08%-524.00%-1051.60%-3292.03%-11805.63%-47252.54%-98660.87%-159.00%-9545.88%89.79%-116.88%-77.84%12.45%-12.29%
Net Income2.58M2.15M1.77M327.70K-2.80M-3.96M-7.37M-9.38M-9.68M-5.41M-12.65M-17.03M-17.14M-33.67M-58.60M-79.52M-65.14M-101.22M67.26M-23.72M-28.89M1.51M-85.97M
Net Income Margin23.85%17.33%13.88%3.26%-29.55%-45.21%-126.87%-249.65%-410.09%-323.60%-666.15%-1054.60%-3251.42%-11854.58%-49664.41%-115247.83%-211.24%-13231.50%84.00%-117.45%-101.15%2.25%-131.38%
R&D-7.25M------12.17M4.29M5.16M9.02M5.39M19.19M35.09M47.66M66.17M59.10M35.17M35.82M46.71M47.21M52.78M
R&D as % of Total Revenue-58.41%------515.48%256.51%271.76%558.70%1022.58%6755.99%29741.53%69073.91%214.57%7725.10%43.92%177.36%163.52%70.46%80.67%
Interest Expense0323.70K332.90K308.80K390.80K205.20K449.10K391.40K372.80K238.40K77.60K93.70K541.00K123.00K2.33M10.99M11.45M11.79M4.96M4.41M4.65M4.78M5.51M
Interest Expense % of Total Revenue0.00%2.61%2.61%3.07%4.12%2.34%7.73%10.42%15.79%14.26%4.09%5.80%102.66%43.31%1976.27%15927.54%37.14%1540.92%6.19%21.84%16.27%7.14%8.42%

Balance Sheet

Currency: EUR2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets26.14M30.61M30.83M46.24M40.21M45.99M38.43M31.39M29.08M23.58M29.15M86.37M69.26M166.21M293.18M229.48M309.85M198.61M281.72M215.54M173.87M151.42M157.93M
Total Liabilities17.09M16.61M17.45M18.47M14.85M23.61M22.91M23.00M24.62M16.75M15.06M15.94M13.84M23.42M188.95M208.54M225.79M214.78M162.62M121.01M105.92M82.20M181.58M
Total Equity8.86M11.53M13.34M27.77M25.37M22.38M15.52M8.39M4.46M6.83M14.09M70.43M55.42M142.80M104.23M20.94M84.06M-16.16M119.10M94.53M67.95M69.22M-23.64M
Cash-594.60K12.50M22.37M15.83M16.87M17.43M13.94M12.80M6.30M20.92M76.00M60.11M152.28M273.82M207.24M276.75M171.03M258.76M136.00M77.79M81.79M101.09M
Total Debt-6.99M5.63M4.42M3.70M10.15M9.77M-14.10M10.70M7.35M6.60M5.71M6.25M163.75M169.59M183.62M185.69M74.23M75.28M70.18M62.13M150.69M
Net Debt-6.39M-6.86M-17.96M-12.13M-6.72M-7.67M-13.94M1.29M4.40M-13.57M-69.41M-54.41M-146.03M-110.07M-37.66M-93.13M14.66M-184.52M-60.73M-7.61M-19.66M49.59M

Cash Flow

Currency: EUR2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.75M3.89M1.68M-1.74M-4.81M-5.16M-221.00K-5.39M-7.11M-7.86M-9.19M-15.49M-14.87M-27.23M-49.86M-56.08M-47.68M-96.37M99.92M-72.64M-55.43M15.55M-25.32M
Investing Cash Flow--165.60K-264.20K-1.41M-468.00K103.40K664.90K-217.80K-108.90K-294.60K7.32M-5.01M3.50M-2.09M-2.95M-3.99M327.00K-966.00K-3.38M-46.27M2.23M-1.04M-3.63M
Financing Cash Flow371.00K-207.60K-940.10K12.62M-1.26M6.10M119.50K2.09M6.11M1.65M16.49M71.53M-520.00K121.48M174.35M-6.51M116.86M-8.26M-8.92M-3.79M-5.10M-10.57M48.07M
Capital Expenditure1.05M332.70K249.70K1.01M541.20K464.70K275.50K190.20K112.70K294.00K239.60K721.00K790.00K2.04M2.80M2.94M2.03M900.00K537.00K02.49M979.00K1.39M
Free Cash Flow-3.56M1.43M-2.76M-5.36M-5.63M-496.50K-5.58M-7.23M-8.16M-9.43M-16.21M-15.66M-29.26M-52.66M-59.02M-49.71M-97.27M99.38M-72.64M-57.92M14.22M-26.71M
Dividends Paid-------------0000000---
FCF to OCF-91.45%85.10%158.10%111.24%109.00%224.66%103.53%101.58%103.74%102.61%104.65%105.31%107.48%105.62%105.24%104.26%100.93%99.46%100.00%104.49%91.46%105.47%
Dividend Paid to FCF-------------0.00%0.00%0.00%0.00%0.00%0.00%0.00%---

Earnings

Report DateJun 30, 2004Dec 31, 2004Mar 31, 2005Jun 30, 2005Sep 30, 2005Dec 31, 2005Mar 31, 2006Jun 30, 2006Sep 30, 2006Dec 31, 2006Mar 31, 2007Jun 30, 2007Sep 30, 2007Dec 31, 2007Mar 31, 2008Jun 30, 2008Sep 30, 2008Dec 31, 2008Mar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Dec 31, 2016Mar 31, 2017Sep 25, 2017Mar 13, 2018Mar 31, 2018Sep 24, 2018Feb 5, 2019Mar 31, 2019Sep 30, 2019Dec 31, 2019Sep 30, 2020Dec 31, 2020Sep 29, 2021Dec 31, 2021Sep 28, 2022Feb 7, 2023Sep 20, 2023Dec 31, 2023Sep 19, 2024Dec 31, 2024Sep 22, 2025Dec 31, 2025Sep 29, 2026Apr 5, 2027
EPS Estimate--------------------------------------------------0.00-0.92-0.00-1.06--0.70--1.44----0.23-0.83-0.24-0.31-0.11---
EPS Actual0.100.090.090.170.090.060.060.010.060.010.000.000.00-0.25-0.09-0.17-0.09-0.17-0.16-0.32-0.16-0.32-0.20-0.39-0.20-0.39-0.19-0.38-0.19-0.38-0.09-0.18-0.09-0.18-0.16-0.43--0.23--0.43--0.34--0.37--0.34--0.49-0.75--0.73-1.15--1.11-1.16--0.52-0.36-0.38-1.240.211.02-0.210.000.00-0.160.53-0.58-0.20-1.52--
Surprise----------------------------------------------------25.00%---9.43%-25.71%-73.61%---8.70%100.00%100.00%-70.97%--281.82%---
Timing--------------------------------------------------After-hoursAfter-hours-After-hoursPre-market-After-hours-After-hours-After-hours-After-hours-After-hours-----After-hoursAfter-hours

Key Statistics & Ratios

Market Cap455.88M
Enterprise Value560.58M
Trailing P/E0.00
Forward P/E7.55
Price / Sales7.57
Price / Book7.60
EPS-1.72
Book Value-0.451
Revenue (TTM)60.21M
Gross Profit (TTM)60.21M
EBITDA-60.49M
Profit Margin-169.63%
Operating Margin-34.85%
Return on Equity-5189.63%
Return on Assets-21.06%
Shares Outstanding50.10M
Shares Float41.24M
Beta1.13
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 12, 20161739:1687
  • Jan 9, 20141077:1067